MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-28-2026
Ascendis Pharma A/S ROE Ratio 2011-2026 | ASND
Annual ROE Ratio Ascendis Pharma A/S
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | -43.41 | -49.95 | -36.51 | -46.45 | -66.18 | -38.79 | -27.36 | -21.08 | - | - | - |
All numbers in EUR currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| -21.08 | -66.18 | -41.22 |
Quarterly ROE Ratio Ascendis Pharma A/S
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -37.31 | -45.39 | -34.83 | -54.37 | -35.45 | -48.25 | -52.95 | -53.3 | -44.23 | -48.03 | -39.03 | -27.86 | -20.01 | -31.18 | -38.54 | -36.67 | -29.93 | -46.69 | -52.28 | -69.71 | -57.27 | -57.27 | -40.52 | -16.24 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in EUR currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| -16.24 | -69.71 | -42.39 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Alector
ALEC
|
-466.34 | $ 2.08 | -14.4 % | $ 214 M |  USA |
 |
Acer Therapeutics
ACER
|
156.54 | - | 2.71 % | $ 14 M | USA |
 |
BioCardia
BCDA
|
721.83 | $ 1.36 | 5.04 % | $ 28.8 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
BioLineRx Ltd.
BLRX
|
-136.27 | $ 2.8 | -1.06 % | $ 908 M |  Israel |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
AgeX Therapeutics
AGE
|
-270.67 | - | -10.17 % | $ 12.2 K | USA |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
BioXcel Therapeutics
BTAI
|
64.02 | $ 1.63 | -2.37 % | $ 4.13 M | USA |
 |
AbCellera Biologics
ABCL
|
-15.14 | $ 3.65 | 0.97 % | $ 1.09 B |  Canada |
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M | USA |
 |
Burford Capital Limited
BUR
|
10.1 | $ 8.81 | 4.38 % | $ 1.39 B |  Britain |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M | Britain |
 |
BeyondSpring
BYSI
|
33.81 | $ 1.36 | 0.37 % | $ 54.8 M | USA |
 |
Cabaletta Bio
CABA
|
-28.65 | $ 3.36 | 1.05 % | $ 3.92 M | USA |
 |
Black Diamond Therapeutics
BDTX
|
-83.66 | $ 2.38 | -3.64 % | $ 131 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-144.96 | $ 4.83 | 1.68 % | $ 10.5 B | Israel |
 |
Capricor Therapeutics
CAPR
|
-98.61 | $ 26.89 | -3.72 % | $ 720 M | USA |
 |
ARCA biopharma
ABIO
|
-21.9 | - | 1052.0 % | $ 415 M | USA |
 |
Acorda Therapeutics
ACOR
|
160.08 | - | -24.86 % | $ 820 K | USA |
 |
Acasti Pharma
ACST
|
-14.36 | - | 4.01 % | $ 150 M | Canada |
 |
Catalyst Biosciences
CBIO
|
540.06 | $ 11.55 | -4.47 % | $ 760 M | USA |
 |
Adverum Biotechnologies
ADVM
|
-185.15 | - | - | $ 86.2 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
AIkido Pharma
AIKI
|
-36.89 | - | 1.93 % | $ 17.4 M | USA |
 |
C4 Therapeutics
CCCC
|
-40.92 | $ 3.04 | 12.59 % | $ 252 M | USA |
 |
Akero Therapeutics
AKRO
|
-33.6 | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Albireo Pharma
ALBO
|
-19.38 | - | -0.23 % | $ 916 M | USA |
 |
Allena Pharmaceuticals
ALNA
|
-257.91 | - | 3.16 % | $ 1.9 M | USA |
 |
Codexis
CDXS
|
-97.53 | $ 1.08 | 6.93 % | $ 79.3 M | USA |
 |
Aileron Therapeutics
ALRN
|
-115.61 | - | 10.36 % | $ 9.8 M | USA |
 |
AlloVir
ALVR
|
-51.87 | - | 4.14 % | $ 49.1 M | USA |
 |
Alpine Immune Sciences
ALPN
|
-32.19 | - | - | $ 2.17 B | USA |
 |
Cerus Corporation
CERS
|
-37.26 | $ 2.64 | 2.93 % | $ 487 M | USA |
 |
Certara
CERT
|
-0.15 | $ 7.17 | 1.2 % | $ 1.15 B | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M | Canada |
 |
Cullinan Management
CGEM
|
-28.35 | $ 15.87 | 2.39 % | $ 929 M | USA |
 |
Compugen Ltd.
CGEN
|
-25.92 | $ 2.24 | 23.76 % | $ 201 M | Israel |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
Coherus BioSciences
CHRS
|
122.99 | $ 1.66 | -0.9 % | $ 156 M | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aptose Biosciences
APTO
|
559.76 | - | -45.71 % | $ 1.2 M | Canada |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
Celldex Therapeutics
CLDX
|
-49.08 | $ 30.18 | 0.3 % | $ 2 B | USA |
 |
Cellectis S.A.
CLLS
|
-26.25 | $ 3.88 | - | $ 116 M | France |